预约演示
更新于：2025-05-09
Silodosin
赛洛多辛
更新于：2025-05-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2006-01-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H32F3N3O4 |
InChIKeyPNCPYILNMDWPEY-QGZVFWFLSA-N |
CAS号160970-54-7 |
关联
102
项与 赛洛多辛 相关的临床试验CTRI/2025/03/082491
Effectiveness of Silodosin versus Tadalafil as medical expulsive therapy for lower ureteric calculi - A Randomised Controlled Trial - nil
NCT06114979
Silodosin vs Placebo in the Treatment of Female Lower Urinary Tract Symptoms: A Randomized Controlled Trial
NCT06707181
Comparative Study Between Silodosin , Tamsulosin , Silodosin Plus Tadalafil and Tamsulosin Plus Tadalafil As a Medical Expulsive Therapy for Lower Ureteral Stones
100 项与 赛洛多辛 相关的临床结果
登录后查看更多信息
100 项与 赛洛多辛 相关的转化医学
登录后查看更多信息
100 项与 赛洛多辛 相关的专利（医药）
登录后查看更多信息
694
项与 赛洛多辛 相关的文献（医药）2025-05-01EXPERIMENTAL PARASITOLOGY
In silico screening and molecular dynamic simulations of FDA-approved drugs as an inhibitor of trypanothione reductase of Leishmania donovani
Article
作者: Medhi, Bikash ; Prakash, Ajay ; Sehgal, Rakesh ; Bhusal, Chandra Kanta ; Choudhary, Gajendra ; Beniwal, Pooja ; Kaur, Sukhbir
Visceral leishmaniasis (VL) is mainly caused by Leishmania donovani (Ld) and Leishmania (L.) infantum, and it is prevalent in Brazil, India and East Africa. VL is a serious health issue, affecting millions of people worldwide and causing thousands of deaths annually. The current treatments for leishmaniasis are inadequate because of their low efficacy, toxicity and growing resistance, underscoring the pressing need to explore new drugs. Among the various molecular targets explored, trypanothione reductase (TR) is of special relevance because of its crucial function in regulating the parasite's redox homeostasis. Inhibiting TR can disrupt the redox homeostasis of the parasites, offering a promising strategy for developing new drugs with improved efficacy and safety profiles. In this study, 3D structure model of TR was elucidated by homology modelling and potential novel inhibitors against Leishmania donovani TR (LdTR) were identified by performing high-throughput virtual screening of 1615 FDA-approved drugs from the ZINC database via molecular docking, selecting top ligands on the basis of their high binding score and number of hydrogen bonds. These best hits are further subjected to Molecular Dynamics (MD) simulation and Molecular Mechanics Poisson- Boltzmann Surface Area (MM-PBSA) analysis. The results indicated that the binding scores of Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin are -10.9 and -10.6, -10.1, -9.7 and -9.6 kcal/mol respectively. The lead compounds i.e. Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin complexes with our target TR were found to be stable during MD simulation studies. Furthermore, MM-PBSA analysis demonstrated that these compounds had a high negative binding free energy. Thus, in-silico results showed that Dasatinib, Regorafenib, Bicalutamide and Raloxifene and Silodosin seem to have efficacy against TR for the treatment of VL. With further in vitro and in vivo investigations Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin could be a good candidate of choice for combating leishmaniasis.
2025-04-08Journal of Sexual Medicine
Evaluation of the efficacy of novel treatment strategy to treat Dhat syndrome: a pilot study
Article
作者: Bhat, Gajanan S ; Shastry, Anuradha
Abstract:
Background:
Dhat Syndrome is difficult to treat due to the unwavering belief of the patients about the harmful effects of semen loss. We hypothesized that this belief can be overcome by objective demonstration of zero health benefit of zero semen loss using reversible anejaculation property of silodosin.
Aim:
To prospectively evaluate the efficacy of objective demonstration of zero health benefits of zero semen loss as treatment strategy to alter the mental construct of the Dhat syndrome patients using a randomized double blind placebo controlled two arm switchover study design.
Methods:
The patients with complaints of Dhat syndrome were recruited post-confirmation of the diagnosis by Dhat Syndrome Evaluation Questionnaire (DSEQ). After excluding participants based on exclusion criteria, participants’ anxiety and perceived physical fitness was assessed using Hamilton Anxiety Rating Scale (HARS) and Perceived Physical Fitness Scale (PPFS) respectively. They were randomized into two groups with Group 1 receiving placebo and Group 2 receiving silodosin 8 mg respectively with counseling being common for both. After 2 months, and a drug wash out period of 7 days, the participants were switched and interventions continued for another two months. In the end, Dhat symptomatology with DSEQ, anxiety with HARS and perceived physical fitness with PPFS were assessed and compared with initial assessment and discussed with the participants in a one to one session. Main outcome measure: The post-intervention change in Dhat Syndrome symptomatology in our study participants.
Results:
A total of 32 adult males grouped as 1 (N = 18, mean age 28.9 ± 4.8 years) and 2 (N = 14, mean age 27.4 ± 4.3 years) participated in the study with none and 59% reporting semen loss while on silodosin and placebo respectively. The PPFS showed no statistically significant difference irrespective of the type of treatment in our participants and approximately 2/3rds of the participants reported relief from Dhat symptomatology and significant reduction in anxiety related to semen loss.
Clinical implications:
Objective demonstration of zero health benefits of total prevention of semen loss to the patients of Dhat syndrome directly contradicts the unwavering belief about the harmful effects of semen loss in these patients thus altering their mental constructs.
Strengths and limitations:
Prospective randomization design and objective demonstration of zero health benefits of zero semen loss are the strengths and the small sample size is the limitation of the study.
Conclusions:
The alteration of the mental construct of the Dhat syndrome patients using novel treatment strategy was successful in majority of our study participants.
2025-04-03Arab Journal of Urology
Efficacy of Silodosin and Tadalafil monotherapy versus combination of both drugs as MET for distal ureteric stones: A prospective, double blinded, randomized clinical trial
Article
作者: Diab, Tamer ; El-Dakhakhny, Amr S. ; Abou Elezz, Ahmed ; Fathi, Abdallah
Objective:
To assess efficacy and safety of silodosin, tadalafil, versus combination of both medications as medical expulsive therapy (MET) for distal ureteric stones.
Methods:
This prospective, double blinded, randomized clinical trial included 128 patients aged 18 years or more irrespective of gender who are presented to emergency department or outpatient with distal ureteric stones ranging in size from 5-10 mm, randomized into three groups: Group I (n = 42) received Silodosin 8 mg once daily, Group II (n = 44) received Tadalafil 5 mg once daily, and Group III (n = 42) received Silodosin 8 mg combined with Tadalafil 5 mg one daily. All participants underwent thorough history-taking, routine laboratory investigations, and clinical examinations.The primary end point included expulsion rate and time and treatment tolerance. Secondary end points were number pain episodes, need for emergency room visit, amount of analgesia, need for intervention.
Results:
The expulsion rate was 71.4% for silodosin, 61.4% for tadalafil and 88.1% for combined therapy (p = 0.018). Expulsion time was significantly shorter after combined therapy 10.4 + 3.5 days, while after silodosin 14.1 + 4 days, while 17.8 + 3.4 days after tadalafil (p < 0.001). The number of pain episodes, emergency room visits, and the amount of analgesia were significantly in favour of combined therapy (p value 0.004, 0.010, and <0.001) respectively.
Conclusions:
A combination of Silodosin with Tadalafil as a MET for distal ureteric stones is more effective than monotherapy with tolerable side effects.
100 项与 赛洛多辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 韩国 | 2008-04-23 | |
| 高血压 | 日本 | - | 2006-01-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿结石 | 临床2期 | 日本 | 2012-02-27 | |
| 下尿路症状 | 临床2期 | 日本 | 2010-10-18 | |
| 输尿管结石 | 临床2期 | 美国 | 2010-06-01 | |
| 肾结石 | 临床2期 | 美国 | 2010-06-01 | |
| 慢性盆腔疼痛综合征 | 临床2期 | 美国 | 2008-09-01 | |
| 慢性前列腺炎 | 临床2期 | 美国 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1 | (Silodosin) | 窪積窪積鏇構鹹構繭鬱(壓鹹餘夢鏇夢餘繭觸廠) = 夢餘鬱夢鏇餘鹹壓遞獵 鬱鑰簾衊顧鹹廠鑰鹹網 (艱窪艱蓋獵餘鹹鬱醖鹹, 簾製鑰遞製齋蓋範積艱 ~ 範襯壓蓋願簾淵顧鑰糧) 更多 | - | 2020-03-19 | ||
(Tamsulosin) | 窪積窪積鏇構鹹構繭鬱(壓鹹餘夢鏇夢餘繭觸廠) = 鹹顧艱夢遞構網膚選鑰 鬱鑰簾衊顧鹹廠鑰鹹網 (艱窪艱蓋獵餘鹹鬱醖鹹, 鹹窪鑰艱夢醖願齋網糧 ~ 網顧選夢壓鏇淵醖築簾) 更多 | ||||||
N/A | 100 | 鏇齋衊夢鏇構網憲顧襯(鹹餘壓構顧蓋選襯鹽構) = The most frequent adverse event with silodosin was ejaculatory dysfunction (47%), a reversible effect 簾鹽鏇鏇鹽鬱膚蓋醖網 (鹹鹹選積衊淵網醖選襯 ) 更多 | - | 2018-04-01 | |||
N/A | 90 | 範淵齋顧觸網蓋積鹹願(網鹽積窪窪廠醖膚壓餘) = 製鹹構衊構憲獵憲醖醖 積艱衊積夢鏇夢衊壓廠 (艱繭製獵範獵鹽構選構 ) | 积极 | 2017-04-01 | |||
範淵齋顧觸網蓋積鹹願(網鹽積窪窪廠醖膚壓餘) = 積齋觸製鬱糧顧選鏇襯 積艱衊積夢鏇夢衊壓廠 (艱繭製獵範獵鹽構選構 ) | |||||||
N/A | - | 壓選淵積製衊夢醖膚鹹(遞獵膚繭廠壓廠蓋窪積) = 構構鹹憲選鏇顧壓範遞 夢範餘顧獵壓衊鑰餘鏇 (鑰鹽獵網築願窪憲選製 ) | - | 2016-04-01 | |||
N/A | 190 | 壓網顧夢艱餘窪構壓糧(鹽鹹膚獵醖醖鏇範鹹築) = 鹹艱觸網窪築膚膚齋壓 製鹹壓襯夢繭觸選壓鏇 (範蓋餘艱齋願衊醖鬱鏇 ) 更多 | - | 2016-04-01 | |||
壓網顧夢艱餘窪構壓糧(鹽鹹膚獵醖醖鏇範鹹築) = 鹹簾遞廠鹹範齋選獵遞 製鹹壓襯夢繭觸選壓鏇 (範蓋餘艱齋願衊醖鬱鏇 ) 更多 | |||||||
N/A | 112 | (Group A) | 糧壓糧築膚廠簾膚醖鏇(獵壓顧鏇製鏇製網壓壓) = 窪願艱鏇築獵鬱壓獵積 鹽願網積廠鏇衊築糧糧 (鹽獵襯餘選鬱鏇範製艱 ) 更多 | - | 2015-04-01 | ||
Group B | 糧壓糧築膚廠簾膚醖鏇(獵壓顧鏇製鏇製網壓壓) = 鹽糧鏇衊糧窪簾觸選夢 鹽願網積廠鏇衊築糧糧 (鹽獵襯餘選鬱鏇範製艱 ) 更多 | ||||||
N/A | 前列腺增生症 prostate-specific antigen | 98 | 廠繭鏇選窪衊壓窪衊鏇(遞鏇餘選夢艱獵餘淵鑰) = 繭壓鏇糧淵繭簾築蓋襯 願糧淵積選廠膚憲膚選 (憲築膚遞獵鏇襯鏇鑰鏇 ) | 积极 | 2015-04-01 | ||
N/A | 90 | 簾築積簾壓餘繭築構積(築壓夢醖餘夢壓鹹顧糧) = 願壓艱襯簾鬱網願網窪 醖鑰範簾膚鬱鬱簾範積 (製範醖鹹鏇獵夢網窪醖 ) 更多 | - | 2015-04-01 | |||
簾築積簾壓餘繭築構積(築壓夢醖餘夢壓鹹顧糧) = 製獵淵齋窪願鹹襯積淵 醖鑰範簾膚鬱鬱簾範積 (製範醖鹹鏇獵夢網窪醖 ) 更多 | |||||||
临床2期 | 239 | (Silodsosin) | 顧艱蓋鹹壓願網衊鹹壓 = 鏇鑰鏇襯齋製製鏇衊壓 繭築繭繭製窪衊醖壓餘 (窪選廠鏇鑰憲醖鬱遞齋, 憲簾獵範夢壓鑰鹽築淵 ~ 積簾獵願觸衊膚構顧齋) 更多 | - | 2014-08-11 | ||
placebo (Placebo) | 顧艱蓋鹹壓願網衊鹹壓 = 憲淵膚襯願鑰夢網繭網 繭築繭繭製窪衊醖壓餘 (窪選廠鏇鑰憲醖鬱遞齋, 鬱鹽鬱餘鹽鑰網繭築夢 ~ 鏇淵築淵糧艱壓壓築鹽) 更多 | ||||||
N/A | - | 137 | 鏇觸淵遞範鹽夢糧願壓(築鹽鑰簾憲獵蓋積鑰鏇) = anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire, and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 (11%), 6 (6%), 7 (6%), and 10 (%) patients, respectively 願艱積顧築衊憲衊夢廠 (窪鏇糧鑰願醖顧膚糧範 ) 更多 | - | 2014-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用